Cardiome Gets Lifeline with Merck Deal

By Taskin Ahmed

Pharma Deals Review: Vol 2009 Issue 4 (Table of Contents)

Published: 10 Apr-2009

DOI: 10.3833/pdr.v2009.i4.1091     ISSN: 1756-7874

Section: Licensing

Fulltext:

Abstract

Cardiome Pharma has signed an agreement with Merck and Co Inc to jointly develop vernakalant, a experimental drug to treat atrial fibrillation, in a deal that could be worth more than US$600 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details